NCT04736745

Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines.

A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled Dose Escalation and Dose Finding Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Ipsen · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the protocol, is to assess the safety and efficacy profile of IPN59011 compared to a placebo. IPN59011 is expected to work longer than product already marketed in the treatment of subjects with moderate to severe facial wrinkles.

Conditions

• Moderate Upper Facial Lines
• Severe Upper Facial Lines

Interventions

Type	Name	Description
BIOLOGICAL	IPN59011	Powder and solvent for solution for injection
BIOLOGICAL	Azzalure	Powder for solution for injection
DRUG	Placebo	Powder for solution for injection

Timeline

• Start date: 2021-02-10
• Primary completion: 2022-10-28
• Completion: 2022-10-28
• First posted: 2021-02-03
• Last updated: 2023-07-14

Locations

1 site across 1 country: Germany